Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach

利用系统血清学方法剖析人体对MVA载体MERS-CoV疫苗的体液免疫反应

阅读:4
作者:Leonie M Weskamm ,Paulina Tarnow ,Charlotte Harms ,Melanie Huchon ,Matthijs P Raadsen ,Monika Friedrich ,Laura Rübenacker ,Cordula Grüttner ,Mariana G Garcia ,Stephan Becker ,Gerd Sutter ,Edouard Lhomme ,Bart L Haagmans ,Anahita Fathi ,Sandra M Blois ,Christine Dahlke ,Laura Richert ,Marylyn M Addo

Abstract

Besides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。